Key result
Advancing HFmrEF and HFpEF therapy requires precision phenotyping and matched interventions over blanket approaches.
Why the study?
HFmrEF and HFpEF represent over half of heart failure cases but lack proven effective therapies beyond SGLT2 inhibitors and diuretics, representing heterogeneous conditions that require precision phenotyping for tailored therapies.
This review highlights the need for precision phenotyping and targeted therapies in HFmrEF and HFpEF to improve outcomes beyond current blanket approaches.
Precision phenotyping may guide future HFmrEF/HFpEF care; leaves open which subtypes respond to targeted therapies.
Heart failure with mid-range ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) represent over half of heart failure cases but lack proven effective therapies beyond sodium-glucose cotransporter 2 inhibitor and diuretics. HFmrEF and HFpEF are heterogeneous conditions requiring precision phenotyping to enable tailored therapies. This review covers concepts on precision medicine approaches for HFmrEF and HFpEF. Areas discussed include HFmrEF mechanisms, anti-inflammatory and antifibrotic treatments for obesity-related HFpEF, If inhibition for HFpEF with atrial fibrillation, and mineralocorticoid receptor antagonism for chronic kidney disease-HFpEF. Incorporating precision phenotyping and matched interventions in HFmrEF and HFpEF trials will further advance therapy compared to blanket approaches.
No takes yet. Share an insight, caveat, or question.
Rosano et al. (2024) conducted a review in Heart failure with mid-range ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF). Heart failure with mid-range and preserved ejection fraction are heterogeneous conditions that require precision phenotyping and matched interventions to advance therapy compared to blanket approaches.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: